Cardiac time-harmonic elastography detected higher myocardial shear wave speed in wild-type transthyretin amyloidosis (3.0 m/sec) compared to healthy controls (1.8 m/sec, P<.05).
Observational (n=109)
Can cardiac time-harmonic elastography (THE) accurately quantify diastolic myocardial stiffness and differentiate between healthy controls, patients with moderate LVH, and patients with wild-type transthyretin amyloidosis?
Cardiac time-harmonic elastography is a reproducible, ultrasound-based method capable of detecting increased diastolic myocardial stiffness in patients with wild-type transthyretin amyloidosis and moderate left ventricular hypertrophy.
Effect estimate: AUC 0.991
Absolute Event Rate: 3% vs 1.8%
p-value: p=<.05
OBJECTIVES: Heart failure is an increasing global health problem. Approximately 50% of patients with heart failure have heart failure with preserved ejection fraction (HFpEF) and concomitant diastolic dysfunction (DD), in part caused by increased myocardial stiffness not detectable by standard echocardiography. While elastography can map tissue stiffness, cardiac applications are currently limited, especially in patients with a higher body mass index. Therefore, we developed cardiac time-harmonic elastography (THE) to detect abnormal diastolic myocardial stiffness associated with DD. MATERIAL AND METHODS: Cardiac THE was developed using standard medical ultrasound and continuous external vibration for regionally resolved mapping of diastolic shear wave speed as a proxy for myocardial stiffness. The method was prospectively applied to 54 healthy controls (26 women), 10 patients with moderate left ventricular hypertrophy (mLVH; 5 women), and 45 patients with wild-type transthyretin amyloidosis (wTTR; 4 women), 20 of whom were treated with tafamidis. Ten healthy participants were reinvestigated after 2 to 6 months to analyze test-retest reproducibility by intraclass correlation coefficients. RESULTS: Myocardial shear wave speed was measured with good reproducibility (intraclass correlation coefficient = 0.82) and showed higher values in wTTR (3.0 ± 0.7 m/sec) than in mLVH (2.1 ± 0.6 m/sec) and healthy controls (1.8 ± 0.3 m/sec, all P < .05). Area under the curve values were 0.991 and 0.737 for discriminating wTTR and mLVH from healthy controls, respectively. Shear wave speed was reduced in patients after tafamidis treatment (2.6 ± 0.6 m/sec, P = .04), suggesting the potential value of THE for therapy monitoring. Shear wave speed was quantified in the septum, posterior wall, and an automatically masked region (here stated for the septal region). CONCLUSIONS: Cardiac THE detects abnormal myocardial stiffness in patients with DD with high penetration depth, independent of body mass index and region selection. Based on standard ultrasound components, cardiac THE is cost-effective and has the potential to become a point-of-care method for stiffness-sensitive echocardiography.
Meyer et al. (Fri,) conducted a observational in Diastolic dysfunction, left ventricular hypertrophy, wild-type transthyretin amyloidosis (n=109). Cardiac time-harmonic elastography (THE) vs. Healthy controls was evaluated on Diastolic shear wave speed (AUC 0.991, p=<.05). Cardiac time-harmonic elastography detected higher myocardial shear wave speed in wild-type transthyretin amyloidosis (3.0 m/sec) compared to healthy controls (1.8 m/sec, P<.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: